Atrial fibrillation is the most common sustained cardiac arrhythmia and is associated with substantial increases in the risk of stroke and systemic thromboembolism. With the successful introduction of the first non-vitamin K antagonist direct oral anticoagulant (NOAC) in 2009, the role of vitamin K antagonists has been replaced in most clinical settings except in a few conditions when NOACs are contraindicated. Data for the use of NOACs in different clinical scenarios have been accumulating in the recent decade, and a more sophisticated strategy for atrial fibrillation patients is now warranted.
Jan Steffel, Peter Verhamme, Tatjana Potpara, Pierre Albaladejo, Matthias Antz, Lien Desteghe, Karl Georg Hæusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldán, Nigel Rowell, Peter Sinnaeve, Rónán Collins, A. John Camm, Hein Heidbüchel, Professor Gregory Lip, Jeffrey I. Weitz, Laurent Fauchier, Deirdre A. Lane, Giuseppe Boriani, Andreas Goette, Roberto Keegan,
Jan Steffel, Rónán Collins, Matthias Antz, Pieter Cornu, Lien Desteghe, Karl Georg Hæusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldán, Nigel Rowell, Peter Sinnaeve, Thomas Vanassche, Tatjana Potpara, A. John Camm, Hein Heidbüchel, Professor Gregory Lip, Thomas Deneke, Nikolaos Dagres, Giuseppe Boriani, Tze-Fan Chao, Eue-Keun Choi, Mellanie True Hills,
Discussion(0)
No comments yet. Be the first to comment.